# Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

> **NCT05176470** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Richard Wu** · enrollment: 2 (actual)

## Conditions studied

- Locally Advanced Melanoma
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Stage IV Melanoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Lifileucel
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT05176470
- **Lead sponsor:** Richard Wu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2023-07-14
- **Final completion:** 2026-12-31
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176470, "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05176470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*